Clinical Trials Logo

Clinical Trial Summary

Rationale: Patients with indolent or smoldering systemic mastocytosis can have severe disabling symptoms. Almost all patients have fatigue, a compromised quality of life, hampering normal functioning. Because this form of mastocytosis is not considered life-threatening, mast cell eradication has never been applied and patients receive only symptomatic therapy with histamine blockers. Midostaurin, a c-KIT inhibitor has shown activity regarding symptom control and decrease of malignant mast cells in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia


Clinical Trial Description

Objective:

Primary: To study in a pilot phase II trial the efficacy of midostaurin administered at an oral dose of 100 mg twice daily in patients with indolent or smoldering systemic mastocytosis on mediator symptom reduction, documented by the Mastocytosis Symptom Assessment Questionnaire, measured at 3 months.

Secondary:

1. To study whether symptom improvement persists at 6 months, and whether midostaurin can reduce mast cell infiltration in the skin and bone marrow, documented by decrease of serum tryptase, decrease of urticaria pigmentosa and decrease of bone marrow mast cells.

2. To assess safety and tolerability of midostaurin in the above mentioned settings

Study design: Single arm, open label pilot phase II study.

Study population: Adult patients (n=20) with histologically documented systemic mastocytosis, indolent or smoldering subtype, with severe symptoms, not controlled by histamine 1 and 2 blockers.

Intervention: treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01920204
Study type Interventional
Source University Medical Center Groningen
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 2013
Completion date May 2015

See also
  Status Clinical Trial Phase
Recruiting NCT04655118 - Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis Phase 2
Recruiting NCT04910685 - (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis Phase 2/Phase 3
Completed NCT03632811 - Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language
Completed NCT02808793 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 Phase 1
Completed NCT02478957 - Treatment of Indolent Systemic Mastocytosis With PA101 Phase 2
Completed NCT03770273 - Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis Phase 2
Recruiting NCT04333108 - Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Phase 3
Not yet recruiting NCT06210698 - Angioedema Biomarker Research Study
Completed NCT00814073 - Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Phase 3
Active, not recruiting NCT03731260 - (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis Phase 2